Sign in Subscribe
Stock offerings

Spectral Medical Inc. Announces Filing of Base Shelf Prospectus

Strategic Insights

— 2 min read

Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, has filed a preliminary short form base shelf prospectus with the securities regulatory authorities in Canada, allowing the company to qualify the distribution of up to $100 million of securities over a 25-month period. This move aims to provide the company with maximum flexibility and optimize its balance sheet as it prepares for upcoming milestones and catalysts. The specific terms of any offering under the base shelf prospectus will be established in a prospectus supplement, which will be filed with the applicable securities regulators in connection with any such offering.

Key Takeaways:

  • Spectral Medical Inc. has filed a preliminary short form base shelf prospectus with the securities regulatory authorities in Canada, allowing the company to qualify the distribution of up to $100 million of securities over a 25-month period.
  • The base shelf prospectus will enable the company to raise capital through the distribution of common shares, debt securities, subscription receipts, warrants, and units, or any combination thereof, as needed.
  • The company has filed the prospectus to have maximum flexibility and optimize its balance sheet as it prepares for upcoming milestones and catalysts, which may impact the company.
  • The specific terms of any offering under the base shelf prospectus will be established in a prospectus supplement, which will be filed with the applicable securities regulators in connection with any such offering.
  • Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin[TM] ("PMX").
  • PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's FDA cleared Endotoxin Activity Assay (EAA[TM]), the clinically available test for endotoxin in blood.
  • The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics.
  • Endotoxic septic shock is a malignant form of sepsis, affecting approximately 330,000 patients in North America each year.
  • Spectral is listed on the Toronto Stock Exchange under the symbol EDT, and for more information, please visit www.spectraldx.com.

Statistics:

  • Up to $100 million of securities can be distributed over a 25-month period under the base shelf prospectus.
  • The company is seeking U.S. FDA approval for its unique product, Toraymyxin[TM], for the treatment of patients with septic shock.
  • The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone, with a design of 2:1 randomized trial of 150 patients using Bayesian statistics.
  • Approximately 330,000 patients are diagnosed with septic shock in North America each year.
  • PMX has been used safely and effectively over 360,000 times to date.

Sources:

  • Globe Newswire - "Spectral Medical Inc. Announces Filing of Base Shelf Prospectus" (July 4, 2025)
  • Spectral Medical Inc. - "About Spectral" (www.spectraldx.com)

Read more